The Department of War is required to establish an integrated pharmacy benefits program for the Military Health System, involving the selection of pharmaceutical agents for the Uniform Formulary (UF) based on clinical and cost effectiveness. A Request for Quotation (RFQ) has been issued for drug classes under review, with potential awards of Uniform Formulary Blanket Purchase Agreements and Additional Discount Program Agreements. The Pharmacy and Therapeutics Committee will review newly approved drugs, including Bysanti, Idvynso, Nereus, and Zolymbus, during an August 2026 meeting. A pre-quotation teleconference is scheduled for June 10, 2026, with responses to clinical questions due by a specified date. No budget amounts or performance location are specified in the description.